GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Herantis Pharma PLC (OHEL:HRTIS) » Definitions » Price-to-Owner-Earnings

Herantis Pharma (OHEL:HRTIS) Price-to-Owner-Earnings : (As of May. 30, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Herantis Pharma Price-to-Owner-Earnings?

As of today (2025-05-30), Herantis Pharma's share price is €1.38. Herantis Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Herantis Pharma's Price-to-Owner-Earnings or its related term are showing as below:


OHEL:HRTIS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.765
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-30), Herantis Pharma's share price is €1.38. Herantis Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.24. Therefore, Herantis Pharma's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-30), Herantis Pharma's share price is €1.38. Herantis Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.24. Therefore, Herantis Pharma's PE Ratio without NRI for today is At Loss.

During the past 13 years, Herantis Pharma's highest PE Ratio without NRI was 15.07. The lowest was 0.00. And the median was 4.76.


Herantis Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Herantis Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Herantis Pharma Price-to-Owner-Earnings Chart

Herantis Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Herantis Pharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Herantis Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Herantis Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Herantis Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Herantis Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Herantis Pharma's Price-to-Owner-Earnings falls into.


;
;

Herantis Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Herantis Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.38/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Herantis Pharma  (OHEL:HRTIS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Herantis Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Herantis Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Herantis Pharma Business Description

Traded in Other Exchanges
N/A
Address
Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.

Herantis Pharma Headlines

No Headlines